News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Senhwa Biosciences Raises $17 Million Series B


12/12/2013 6:46:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Senhwa Biosciences Raises $17M Series B

SAN DIEGO
and NEW TAIPEI CITY, Taiwan, Dec. 12, 2013 /PRNewswire-iReach/ -- Senhwa Biosciences, Inc. has raised an additional $17 million USD in a Series B financing to drive its anticancer agents through critical clinical trials, the company announced today. The Taiwan and San Diego, CA based company closed the round with participation from existing and new investors including H&Q Asia Pacific, Morningside and China Investment & Development Co., Ltd. Proceeds from the financing will be used to support the continuing development of its first-in-class anticancer agents CX-5461 and CX-4945 and take them through clinical proof-of-concept studies.

(Photo: http://photos.prnewswire.com/prnh/20131212/MN31456)

"Senhwa has made tremendous strides since its inception just one year ago. This round of funding will allow us to continue to advance and keeps us on course to open two new US-based Phase I and Phase II clinical trials during 2014," said Dr. Tai-Sen Soong, President of Senhwa Biosciences. "The level of commitment from new and existing investors reflects the quality of our assets, the confidence our investors have in our management team and it accelerates the development of Senhwa into a fully-fledged clinical development company."

Senhwa's lead anticancer compound for treating hematological malignancies is CX-5461, a p53 activating, Pol I inhibitor, currently in a Phase I clinical trial at the Peter MacCallum Cancer Centre in Melbourne, Australia. CX-5461 has a unique mechanism of action that enables selective activation of p53 in tumor cells but not in normal healthy ones, destroying malignant tissue while sparing the patient from the serious side effects associated with cancer therapies.

Senhwa's CK2 inhibitor, CX-4945, is being developed for combination treatment in solid tumors with the commonly used chemotherapy agents gemcitabine and cisplatin. Pre-clinically, combination of CX-4945 with these DNA damaging agents has been shown to act synergistically to enhance the efficacy of these anticancer treatments.

About Senhwa Biosciences

Senhwa Biosciences identifies and develops innovative therapies that have the potential to fundamentally change the way patients are treated. Our central philosophy is to unearth validated targets or therapies that could significantly improve treatment, but have not yet been properly exploited. As a value-added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through to clinical proof-of-concept.

Senhwa has a strong Management Team with proven track records in developing new drugs and targeted agents. Headquartered in Taiwan, but with a vital operational base in San Diego, California, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global investigators and service providers. Clinical trials are ongoing or planned for Australia and the US, and our service providers work from their bases in North America, Asia, Australia and Europe.For more information on Senhwa and its programs, please visit http://www.senhwabiosciences.com/.

Media Contact:Sean O'Brien, Senhwa Biosciences, 858-552-6808, sobrien@senhwabio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Senhwa Biosciences



Help employers find you! Check out all the jobs and post your resume.
Read at BioSpace.com
Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES